Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

20.83
-0.4300-2.02%
Post-market: 20.83-0.0017-0.01%19:41 EDT
Volume:2.76M
Turnover:57.52M
Market Cap:16.15B
PE:-14.47
High:21.61
Open:21.61
Low:20.55
Close:21.26
52wk High:30.98
52wk Low:13.83
Shares:775.37M
Float Shares:129.00M
Volume Ratio:0.55
T/O Rate:2.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4400
EPS(LYR):-1.4439
ROE:-206.10%
ROA:-115.28%
PB:24.51
PE(LYR):-14.43

Loading ...

Electric Vehicle Adoption Reaches 'Tipping Point' Globally, Trend Deemed Self-Sustaining

Deep News
·
Apr 26

Summit Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Apr 23

Summit partner selection for ASCO plenary signals strong OS, says Leerink

TIPRANKS
·
Apr 22

Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim

TIPRANKS
·
Apr 22

IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio?

Benzinga_recent_news
·
Apr 19

Evercore ISI Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Apr 17

Summit Therapeutics Inc Stock (SMMT) Moved Up by 12.03% on Apr 16: Drivers Behind the Movement

TradingKey
·
Apr 17

Summit Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Price Target $45

THOMSON REUTERS
·
Apr 08

Summit Therapeutics initiated with a Buy at Stifel

TIPRANKS
·
Apr 08

Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)

TIPRANKS
·
Apr 02

Barclays Remains a Hold on Summit Therapeutics (SMMT)

TIPRANKS
·
Mar 30

Summit Therapeutics Links Ivonescimab Brain Metastases Data To November PDUFA

Simply Wall St.
·
Mar 29

Summit Therapeutics presents HARMONi intracranial efficacy findings for ivonescimab plus chemotherapy in EGFR-mutated NSCLC; intracranial PFS HR narrows to 0.53 in patients with baseline brain metastases

Reuters
·
Mar 28

Summit Therapeutics releases HARMONi Phase 3 ivonescimab HRQoL presentation; trial enrollment totals 438 patients

Reuters
·
Mar 28

Summit Therapeutics to present multiple ivonescimab data sets at ELCC 2026

TIPRANKS
·
Mar 27

Summit Therapeutics announces ELCC 2026 presentations; intracranial PFS climbs to 10.1 months on ivonescimab plus chemotherapy in HARMONi patients with baseline brain metastases

Reuters
·
Mar 27

UK Vehicle Production Plummets in February Amid Export Weakness

Deep News
·
Mar 27

Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT)

TIPRANKS
·
Mar 20

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics

Reuters
·
Mar 16

Is Summit Therapeutics (SMMT) Now Pricing In Too Much Hope After Strong Multi Year Gains

Simply Wall St.
·
Mar 04